HF10 THERAPY proven to provide patients superior relief from back pain and leg pain.

The only spinal cord stimulation therapy APPROVED to deliver pain relief without paresthesia.

8 OUT OF 10 people who try HF10 therapy have significant
relief of back pain and leg pain.

HF10^TM Therapy: Sustained Superiority to Traditional SCS at 24 Months¹

HF10 therapy was labeled superior to traditional SCS due to the rigor and outcomes of the SENZA-RCT. The study demonstrated superiority at all primary and secondary endpoints vs traditional SCS.

SENZA-RCT: Responder Rates¹

Superior Long-Term Back and Leg Pain Response with HF10 Therapy

n = 156

p-value back < 0.001

p-value leg = 0.003

SENZA-RCT: Pain Reduction¹

SUPERIOR BACK PAIN RELIEF WITH HF10 THERAPY

SUPERIOR LEG PAIN RELIEF WITH HF10 THERAPY

12 months: n = 171, p-value back < 0.001, p-value leg < 0.001
24 months: n = 156, p-value back < 0.001, p-value leg = 0.027

SENZA-RCT: Functional Outcomes¹

Superior ODI improvement with HF10 therapy

SENZA-RCT: Patients reporting uncomfortable stimulation²

HF10 therapy is the only paresthesia-free SCS therapy

MONTH 3

MONTH 12

HF10 THERAPY	CONTROL (TRADITIONAL)
n=90	n=81
0 (0%)	33 (46.5%)
0 (0%)	28 (44.4%)

SENZA-RCT: Equivalent Safety Profile to Traditional SCS²

Study related serious adverse events (SAEs)

Study related SAEs (including neurological deficit)

SAEs by outcome

Unanticipated device related SAEs

Deaths

HF10 THERAPY		CONTROL (TRADITIONAL)
Number of SAEs	# (%) Subjects with SAEs (n=101)	Number of SAEs	# (%) Subjects with SAEs (n=97)
5	4 (4.0%)	8	7 (7.2%)
0	0 (0.0%)	0	0 (0.0%)

0	0 (0.0%)	0	0 (0.0%)
1	1 (1.0%)	1	1 (1.0%)

HF10 therapy subject death due to hepatocellular carcinoma at month 13; traditional SCS subject death due to myocardial infarction during IPG implant procedure.

Uncomfortable Paresthesias

Implant site pain

Lead migration

HF10 THERAPY		CONTROL (TRADITIONAL)
Number of AEs	# (%) Subjects with AEs (n=101)	Number of AEs	# (%) Subjects with AEs (n=97)
0	0 (0.0%)	11	11 (11.3%)
12	10 (9.9%)	11	10 (10.3%)
3	3 (3.0%)	5	5 (5.2%)

SENZA-RCT & SENZA-EU Studies: Demonstrated Reproducibility^1,3

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.

HF10TM Therapy: Sustained Superiority to Traditional SCS at 24 Months1

SENZA-RCT: Responder Rates1